NewAmsterdam Pharma Company N.V — Cash Flow (NASDAQ:NAMS) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Cash from operating activities —141.22 M158.56 M147.78 M 147.78 M Cash from investing activities —24 K62.85 M174.92 M 174.92 M Cash from financing activities —8.91 M659.51 M29.52 M 29.52 M Free cash flow —141.19 M157.89 M147.54 M 147.54 M

News

Cantor Fitzgerald reiterates NewAmsterdam Pharma stock rating at Overweight

Guggenheim raises NewAmsterdam Pharma stock price target on EU launch timing

NewAmsterdam Pharma earnings missed by $0.23, revenue fell short of estimates

NewAmsterdam expects EMA decision on cholesterol drug in second half 2026

NewAmsterdam Pharma stock price target raised to $55 by Leerink Partners

Piper Sandler highlights commercial biotech names to own in 2026

Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q3 2025 Update

NewAmsterdam Pharma Company N.V. (NAMS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

NewAmsterdam Pharma stock hits all-time high at 41.56 USD

NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating (NASDAQ:NAMS)

NewAmsterdam Pharma stock price target raised to $45 from $44 at Leerink

NewAmsterdam Pharma stock price target raised to $44 by RBC Capital